dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade de São Paulo (USP)
dc.date.accessioned2020-12-12T01:29:44Z
dc.date.accessioned2022-12-19T20:48:20Z
dc.date.available2020-12-12T01:29:44Z
dc.date.available2022-12-19T20:48:20Z
dc.date.created2020-12-12T01:29:44Z
dc.date.issued2020-01-01
dc.identifierNatural Product Research.
dc.identifier1478-6427
dc.identifier1478-6419
dc.identifierhttp://hdl.handle.net/11449/199062
dc.identifier10.1080/14786419.2020.1782403
dc.identifier2-s2.0-85087355972
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5379696
dc.description.abstractLeishmaniasis is a group of diseases that have limited and high toxic therapeutic options. Herein, we evaluated the antileishmanial potential and cytotoxicity of hexanic extract obtained from the Antarctic brown alga Ascoseira mirabilis using bioguided fractionation against Leishmania amazonensis and murine macrophages, which was fractionated by SPE, yielding seven fractions (F1-F7). The fraction F6 showed good anti-amastigote activity (IC50 = 73.4 ± 0.4 μg mL−1) and low cytotoxicity (CC50 > 100 μg mL−1). Thus, in order to identify the bioactive constituent(s) of F6, the fraction was separated in a semipreparative HPLC, yielding four fractions (F6.1-F6.4). F6.2 was the most bioactive fraction (IC50 = 66.5 ± 4.5 μg mL−1) and GC-MS analyses revealed that the compounds octadecane, propanoic acid, 1-monomyristin and azelaic acid correspond to 61% of its composition. These data show for the first time the antileishmanial potential of the Antarctic alga A. mirabilis.
dc.languageeng
dc.relationNatural Product Research
dc.sourceScopus
dc.subjectAntarctic macroalgae
dc.subjectAscoseiraceae
dc.subjectBrown algae
dc.subjectCutaneous leishmaniasis
dc.subjectGC-MS
dc.subjectNatural products
dc.titleThe antileishmanial activity of the antarctic brown alga Ascoseira mirabilis Skottsberg
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución